drugset / Trial / NCT04350671

Interferon Beta 1a in Hospitalized COVID-19 Patients

NCT04350671 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.

Timeline

Start
2020-04-15
Primary completion
2020-04-20
Completion
2020-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon beta-1a Protein / enzyme biologic — —
Background Hydroxychloroquine Small molecule — —
Background Lopinavir Other / unclassified — —
Background Ritonavir Other / unclassified — —

Indications